
Hyoscine butylbromide | Drugs | BNF | NICE
MHRA/CHM advice: Hyoscine butylbromide (Buscopan®) injection: risk of serious adverse effects in patients with underlying cardiac disease (February 2017) The MHRA advises that hyoscine …
Buscopan 片剂:用途、副作用、剂量、注意事项等 - doctorspot.in
2024年6月11日 · Buscopan 的通用名是丁溴莨菪碱,是一种解痉药。 它的作用是放松胃肠道和泌尿道的平滑肌,从而缓解肌肉痉挛引起的疼痛和不适。 它通常用于治疗各种涉及肌肉痉挛的 …
Medicinal forms | Hyoscine butylbromide | Drugs | BNF | NICE
Forms available from special-order manufacturers include: oral suspension, oral solution. The content on the NICE BNF site (BNF) is the copyright of BMJ Publishing Group Ltd and the …
Hyoscine butylbromide tablets - Buscopan. (Side effects, dosage)
2023年10月15日 · Hyoscine butylbromide is an antispasmodic medicine which is taken to relieve cramps in the stomach, intestines or bladder. In particular, it helps to ease bloating and the …
Buscopan: medicine to treat stomach cramps and IBS - NHS
Buscopan relieves painful stomach cramps, including those linked with irritable bowel syndrome (IBS). It can also help bladder cramps and period pain. Buscopan contains the active …
Hyoscine butylbromide - Wikipedia
Hyoscine butylbromide, also known as scopolamine butylbromide [4] and sold under the brandname Buscopan among others, [5] is an anticholinergic medication used to treat …
Buscopan - Uses, Side Effects, Interactions - MedBroadcast.com
Hyoscine belongs to the group of medications called antispasmodics. Hyoscine is used to relieve smooth muscle spasms (cramps) in the stomach and intestines and in the bladder and urethra. …
Palliative care - nausea and vomiting: Prescribing hyoscine
Hyoscine butylbromide is an antimuscarinic medication that is poorly absorbed orally. For the management of nausea and vomiting it should be given as a subcutaneous bolus dose or by …
丁基东莨菪碱 - 百度百科
丁基东莨菪碱是一种药物,主要用于治疗胃肠痉挛,它中断蕈毒碱型乙酰胆碱受器,因此是一种受体拮抗剂,它以其溴盐溴化-N-丁基东莨菪碱的形式作为胃肠解痉药被使用。 它由德国的勃林 …
Hyoscine butylbromide | Drugs | BNFC | NICE
MHRA/CHM advice: Hyoscine butylbromide (Buscopan®) injection: risk of serious adverse effects in patients with underlying cardiac disease (February 2017) The MHRA advises that hyoscine …